Ascend Laboratories, LLC recalled 2,256 bottles of Aripiprazole Tablets on August 28, 2025. The recall followed reports that the drug may be superpotent, posing serious health risks. Consumers should stop using the product immediately and consult healthcare providers.
Superpotent drug
Consumers and healthcare providers should stop using this product immediately. Contact Ascend Laboratories, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Aripiprazole Tablets, USP, 10 mg, sold in 30-count bottles. The lot number is 24144162 and the expiration date is September 2027. The tablets were manufactured by Alken Laboratories Ltd., India, and distributed nationwide by Ascend Laboratories, LLC.
The recall stems from concerns that the Aripiprazole Tablets may be superpotent. This increased potency can lead to severe side effects and adverse reactions in patients.
There are no specific incident reports or injury counts mentioned. However, the potential for serious health risks from superpotent drugs categorizes this recall as high risk.
Consumers and healthcare providers should stop using Aripiprazole Tablets immediately. Contact Ascend Laboratories, LLC for guidance or consult your healthcare provider.
For more information, reach Ascend Laboratories, LLC at their office in Parsippany, NJ. Visit the FDA's recall page for further details.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.